ELEVATE – evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
ELEVATE – evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial ; volume:22 ; number:1 ; day:1 ; month:9 ; year:2022 ; pages:1-13 ; date:12.2022
BMC cancer ; 22, Heft 1 (1.9.2022), 1-13, 12.2022
- Creator
-
Smyth, Elizabeth
Cozens, Kelly
Griffiths, Daniel
Clark, Kathryn L.
Ewings, Sean
Petty, Russell
Underwood, Tim
Fitzgerald, Rebecca C.
Tanner, James
Giger, Olivier
Anand, Shubha
Griffiths, Gareth
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-022-09891-9
- URN
-
urn:nbn:de:101:1-2022111909214823768579
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Smyth, Elizabeth
- Cozens, Kelly
- Griffiths, Daniel
- Clark, Kathryn L.
- Ewings, Sean
- Petty, Russell
- Underwood, Tim
- Fitzgerald, Rebecca C.
- Tanner, James
- Giger, Olivier
- Anand, Shubha
- Griffiths, Gareth
- SpringerLink (Online service)
Other Objects (12)
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies
Stanniocalcin-1 promotes temozolomide resistance of glioblastoma through regulation of MGMT
Mitochondria‐Targeted Temozolomide Probe for Overcoming MGMT‐Mediated Resistance in Glioblastoma
Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit
A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma
Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma
Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies
Stanniocalcin-1 promotes temozolomide resistance of glioblastoma through regulation of MGMT
Mitochondria‐Targeted Temozolomide Probe for Overcoming MGMT‐Mediated Resistance in Glioblastoma
Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit
A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma
Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma
Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies
Stanniocalcin-1 promotes temozolomide resistance of glioblastoma through regulation of MGMT
Mitochondria‐Targeted Temozolomide Probe for Overcoming MGMT‐Mediated Resistance in Glioblastoma
Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit
A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma
Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma